MHRA sets out Brexit implementation period plan
pharmafile | August 7, 2018 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EU, MHRA, UK, brexit, implentation period
The UK Medicines and Healthcare products Regulatory Agency (MHRA) have released an update which sets out what pharmaceutical and healthcare companies should expect from the Brexit implementation period that will run from March 2019 to December 2020.
Before the implementation period, the UK will remain a full member of the European Union. This will mean that the UK will retain all of the rights and obligations associated with EU membership.
During the implementation period UK businesses will have the same rights as EU-based businesses to have their cases accepted and processed by EU-based ‘leading authorities’. Meanwhile, pharmaceutical firms will be allowed to continue to undertake batch release testing and Qualified Person certification in the UK. These certificates will be recognised in the EU and EU certification will be recognised in the UK.
Furthermore, marketing authorisation holders and Qualified Persons for Pharmacovigilance (QPPVs) will be allowed to remain in the UK and will be allowed access to EU markets. There will be continued mutual recognition of manufacturing and distribution licenses and associated inspections.
Additionally, companies based in the UK will be able to continue to apply for marketing authorisations via either the centralised or decentralised procedures. However the UK will lose the right to vote in EMA and EU committees during the implementation period.
In regards to the period following the UK’s exit from the European Union the MHRA suggested that: “Progress is being made to finalise the Withdrawal Agreement as a whole. We will aim to agree this by October, alongside the framework for our future relationship with the EU.”
In response, Dr Sheuli Porkess, Deputy Chief Scientific Officer for the ABPI said: “Today’s guidance from Government is welcome, as is the reiteration of the UK’s preference for close cooperation with the EU across all aspects of medicines regulation.”
However the industry lobby chief noted that: “There are still some unanswered questions. We are clear that there needs to be an implementation period but whether there will be one is still subject to negotiation. The document also states that the future role of the MHRA, whose expertise is vital, is also still being discussed. The industry will continue to plan for all scenarios, including ‘no deal’. We believe that the best way to protect patients and public health is for the EU and UK to agree continued cooperation on the regulation of medicines.”
Louis Goss
Related Content
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
IMed Consultancy releases white paper on Digital Mental Health Technologies
IMed Consultancy, a consultancy and service provider for the medical and health technology sector, has …
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
